NO20065144L - Krystallinsk clopidogrelnaftalensulfonat eller hydrat derav, fremgangsmate for fremstilling derav, og farmasoytisk preparat inneholdende dette - Google Patents

Krystallinsk clopidogrelnaftalensulfonat eller hydrat derav, fremgangsmate for fremstilling derav, og farmasoytisk preparat inneholdende dette

Info

Publication number
NO20065144L
NO20065144L NO20065144A NO20065144A NO20065144L NO 20065144 L NO20065144 L NO 20065144L NO 20065144 A NO20065144 A NO 20065144A NO 20065144 A NO20065144 A NO 20065144A NO 20065144 L NO20065144 L NO 20065144L
Authority
NO
Norway
Prior art keywords
hydrate
preparation
pharmaceutical composition
composition containing
crystalline clopidogrel
Prior art date
Application number
NO20065144A
Other languages
English (en)
Norwegian (no)
Inventor
Gwan Sun Lee
Sangmin Yun
Eun Sook Kim
Hee Seock Kim
Bo Sung Kwon
Cheol Kyung Kim
Han Kyong Kim
Kwee-Hyun Suh
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020040041309A external-priority patent/KR100563455B1/ko
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of NO20065144L publication Critical patent/NO20065144L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20065144A 2004-04-09 2006-11-08 Krystallinsk clopidogrelnaftalensulfonat eller hydrat derav, fremgangsmate for fremstilling derav, og farmasoytisk preparat inneholdende dette NO20065144L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20040024361 2004-04-09
KR1020040041309A KR100563455B1 (ko) 2004-04-09 2004-06-07 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물
PCT/KR2004/002665 WO2005097804A1 (fr) 2004-04-09 2004-10-18 Naphthalenesulfonate cristallin de clopidogrel ou hydrate de celui-ci, procede permettant de le preparer et composition pharmaceutique le contenant

Publications (1)

Publication Number Publication Date
NO20065144L true NO20065144L (no) 2007-01-08

Family

ID=35061381

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065144A NO20065144L (no) 2004-04-09 2006-11-08 Krystallinsk clopidogrelnaftalensulfonat eller hydrat derav, fremgangsmate for fremstilling derav, og farmasoytisk preparat inneholdende dette

Country Status (13)

Country Link
US (1) US7470707B2 (fr)
EP (2) EP1732932B1 (fr)
JP (1) JP4550884B2 (fr)
CN (1) CN1938319B (fr)
AU (1) AU2004318214B2 (fr)
BR (1) BRPI0418726A (fr)
CA (1) CA2562532C (fr)
HK (1) HK1098482A1 (fr)
IL (1) IL177806A0 (fr)
NO (1) NO20065144L (fr)
NZ (1) NZ551153A (fr)
RU (1) RU2328501C1 (fr)
WO (1) WO2005097804A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063708A2 (fr) * 2003-11-03 2005-07-14 Cadila Healthcare Limited Procede de preparation de differentes formes de (s)-(+)- clopidogrel bisulfate
GB0418580D0 (en) * 2004-08-21 2004-09-22 Ivax Pharmaceuticals Sro Clopidogrel salt
IS2385B (is) * 2006-02-10 2008-07-15 Actavis Group Hf. Klópidógrel bísúlfat lyfjasamsetningar
KR100945062B1 (ko) 2006-03-22 2010-03-05 한미약품 주식회사 클로피도그렐 1,5-나프탈렌디술폰산염 및 이의 수화물의제조방법
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
RU2470636C2 (ru) * 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
EP2107061A1 (fr) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation de clopidogrel enrichi optiquement
PT3100728T (pt) 2009-05-13 2020-02-21 Cydex Pharmaceuticals Inc Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos
EP2578570A1 (fr) 2011-10-07 2013-04-10 Almirall, S.A. Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
CN111620795B (zh) * 2020-04-27 2021-11-19 华东师范大学 芳基、烷基磺酸类化合物及采用无机硫盐的构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
JP2815691B2 (ja) * 1990-09-20 1998-10-27 麒麟麦酒株式会社 Ｋｒｎ２３９１酸付加塩およびその用途
US6133244A (en) * 1993-10-22 2000-10-17 Institut Pasteur Method for immunization against hepatitis B
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
ATE349451T1 (de) 2001-01-24 2007-01-15 Cadila Healthcare Ltd Verfahren zur herstellung von clopidogrel
AU2002366383B2 (en) * 2001-12-18 2007-06-14 Teva Pharmaceutical Industries Ltd. Polymorphs of clopidogrel hydrogensulfate
HUP0200438A3 (en) * 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
CZ297472B6 (cs) * 2002-08-27 2006-12-13 Zentiva, A.S. Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
GB2393181A (en) * 2002-09-19 2004-03-24 Cipla Ltd Amorphous clopidogrel
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
EP1720884A1 (fr) * 2004-02-24 2006-11-15 Siegfried Generics International AG Sels de clopidogrel acceptables d'un point de vue pharmacologique
EP1740594A1 (fr) * 2004-04-20 2007-01-10 Sanofi-Aventis Sel de clopidogrel et formes polymorphes associees

Also Published As

Publication number Publication date
US20050228012A1 (en) 2005-10-13
AU2004318214A1 (en) 2005-10-20
CN1938319A (zh) 2007-03-28
JP2007532530A (ja) 2007-11-15
JP4550884B2 (ja) 2010-09-22
EP1732932A1 (fr) 2006-12-20
IL177806A0 (en) 2006-12-31
CA2562532C (fr) 2010-02-16
WO2005097804A1 (fr) 2005-10-20
EP2386560A1 (fr) 2011-11-16
RU2328501C1 (ru) 2008-07-10
CN1938319B (zh) 2010-05-12
AU2004318214B2 (en) 2007-12-06
CA2562532A1 (fr) 2005-10-20
EP1732932A4 (fr) 2010-04-21
US7470707B2 (en) 2008-12-30
BRPI0418726A (pt) 2007-09-11
EP1732932B1 (fr) 2012-03-21
HK1098482A1 (en) 2007-07-20
NZ551153A (en) 2009-10-30

Similar Documents

Publication Publication Date Title
NO20065144L (no) Krystallinsk clopidogrelnaftalensulfonat eller hydrat derav, fremgangsmate for fremstilling derav, og farmasoytisk preparat inneholdende dette
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
DK2044076T3 (da) Fremgangsmåde til fremstilling af asenapin og intermediatprodukter, som anvendes i fremgangsmåden
DK1695965T3 (da) Krystallinsk betaform af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famceutiske sammensætninger indeholdende denne
UY29479A1 (es) Inhibidores de adn-pk
CL2007003791A1 (es) Compuestos derivados de piperidina, inhibidores de la proteina quinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para inhibir el crecimiento celular anormal.
EP1832298A4 (fr) Preparation a liberation controlee de type a matrice comprenant une substance basique ou un sel de celle-ci et procede pour la production de celle-ci
DK1598333T3 (da) Fremgangsmåde til fremstilling af (1S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutan og syreadditionssalte heraf samt anvendelse til syntese af ivabradin og syreadditionssalte heraf med farmaceutisk acceptable syrer
DK1695709T3 (da) Krystalinsk gammad-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
NO20080784L (no) Histondeacetylaseinhibitorer
FI20055416A0 (fi) Bioabsorvoituva nauhajärjestelmä, bioabsorboituva nauha, menetelmä bioabsorboituvan nauhan valmistamiseksi, bioabsorboituvan nauhan neulajärjestelmä sekä lukitusmekanismi
DK1707562T3 (da) Krystallinsk v-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famaceutiske sammensætninger, som indeholder denne
DK3219328T3 (da) Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
DK1711494T3 (da) Arylsubstituerede heterocykler, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
NO20064454L (no) Matstang og fremgangsmåte for fremstilling derav.
NO2013008I1 (no) Krizotinib eller et farmasøytisk akseptabelt salt,hydrat eller solvat derav
PT1877409E (pt) Pirrolopiridinas substituídas, composições contendo-as, processo de fabrico e utilização
NO20082395L (no) Krystallinske former av 1'-(1-metyl)-4'-[(2-fluor-4-metoksyfenyl)metyl]-5'-metyl-1H-pyrazol-3'-O-beta-D-glucopyranosid, en fremstillingsmetode og anvendelse av denne for fremstilling av medikamenter
DK1695710T3 (da) Krystallinsk betad-form af ivabradinhydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
IL179424A0 (en) Substituted oxazole -benzoisothiazole dioxide derivatives, process for their preparation and their use
DK1670458T3 (da) 1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika
NO20082256L (no) Pyrazolderivater, preparater som inneholder slike forbindelser, og fremgangsmåter for anvendelse
DE602004013405D1 (de) Polymorphe formen von valsartan
NO20053809D0 (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
DE602005015459D1 (de) Folienherstellungsverfahren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application